Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts

Inflammation Research

Volumn 57, Issue 1, 2008, Pages 4-10

  Manabe, H ^a   Nasu, Y ^a   Komiyama, T ^a   Furumatsu, T ^a,b   Kitamura, A ^a   Miyazawa, S ^a   Ninomiya, Y ^a   Ozaki, T ^a   Asahara, H ^b,c   Nishida, K ^a,d  

^a OKAYAMA UNIVERSITY   (Japan)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

Histone deacetylase (HDAC); Hypoxia inducible factor 1 (HIF 1); Rheumatoid arthritis; Vascular endothelial growth factor (VEGF)

Indexed keywords

COLLAGEN ANTIBODY; HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ROMIDEPSIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIUM; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; FIBROBLASTS; HISTONE DEACETYLASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED DBA; RNA, MESSENGER; SYNOVIAL MEMBRANE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38349104030     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-007-7036-z     Document Type: Article

References (38)

1. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1258-65.
2. Lund-Olesen K. Oxygen tension in synovial fluids. Arthritis Rheum 1970; 13: 769-76.
3. Walsh DA, Haywood L. Angiogenesis: a therapeutic target in arthritis. Curr Opin Investig Drugs 2001; 2: 1054-63.
4. Schrieber L, Jackson CJ. Angiogenesis in rheumatoid arthritis. In: Klippel JH, Dieppe PA et al, editors. Rheumatology. London: Mosby; 1998. Section 5,12.1-4.
5. Josko J, Mazurek M. Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 2004; 10: RA89-98.
6. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152: 4149-56.
7. Fava RA, Olsen NJ, Spencer-Green G, Yeo Kt, Yeo TK, Berse B et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180: 341-6.
8. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am J Ophthalmol 1978; 86: 455-61.
9. BenEzra D, Hemo I, Maftzir G. In vivo angiogenic activity of inteleukins. Arch Ophthalmol 1990; 108: 573-6.
10. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992; 175: 1135-8.
11. Firestein GS. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 1999; 103: 3-4.
12. Folkman J. Angiogenesis. In: Smolen JS, Lipsky PE, eds. Targeted therapies in rheumatology. London: Martin Dunitz; 2003, p. 111-30.
13. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 2002; 46: 2587-97.
14. Giatromanolaki A, Sivridis E, Maltezos E, Athanassou N, Papazoglou D, Gatter KC et al. Upregulated hypoxia inducible factor-1α and -2α pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003; 5: R193-201.
15. Makino Y, Nakamura H, Ikeda E, Ohnuma K, Yamauchi K, Yabe Y et al. Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol 2003; 15: 6534-40.
16. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-52.
17. Kuo MH, Allis CD. Roles of histone acetyltranferases and deacetylases in gene regulation. Bioessays 1998; 20: 615-26.
18. Hassing CA, Schreiber SL. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1997; 1: 300-8.
19. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW et al. Desipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999; 94: 1401-8.
20. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998; 241: 126-33.
21. Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 2000; 6: 849-66.
22. Kosugi H, Towatari M, Hatano S, Kitamura K, Kiyoi H, Kinoshita T et al. Histone deacetylase inhibitors are the potent inducer / enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 1999; 13: 1316-24.
23. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, Mancini M, Pelicci PG, Lo Coco F, Nervi C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61: 2-7.
24. Kwon HJ, Owa T, Hassig CA, Shimada J, Schreiber SL. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci USA 1998; 95: 3356-61.
25. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW et al. Histone deacetylase induce angiogenesis by negative regulation of tumor suppressor gene. Nat Med 2001; 7: 437-43.
26. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002; 97: 290-6.
27. Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, Matsuo M et al. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol. 2003; 66: 897-906.
28. WAF/Cip1 expression. Arthritis Rheum 2004; 50: 3365-76.
29. Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM. Induction of arthritis with monoclonal antibodies to collagen. J Immunol 1992; 148: 2103-8.
30. Kato H, Nishida K, Yoshida A, Takada I, McCown C, Matsuo M et al. Effect of NOS2 gene deficiency on the development of autoantibody mediated arthritis and subsequent articular cartilage degeneration. J Rheumatol 2003; 30: 247-55.
31. Sancho D, Gomez M, Viedma F, Esplugues E, Gordon-Alonso M, Garcia-Lopez MA et al. CD69 downregulates autoimmune reactivity through active transforming growth factor- production in collagen-induced arthritis. J Clin Invest 2003; 112: 872-82.
32. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem Biophs Res Commun 2003; 300: 241-6.
33. Thornton RD, Lane P, Borghaei RC, Pease EA, Caro J, Mochan E. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 2000; 350: 307-12.
34. Hellwig-Bürgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999; 94: 1561-7.
35. Chung YL, Lee MY, Wang AJ, Yao LF. A Therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003; 8: 707-17.
36. Nonomura Y, Kohsaka H, Nagasaka K, Miyasaka N. Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. J Imumunol 2003; 171: 4913-9.
37. Perlman H, Bradley K, Liu H, Cole S, Shamiyeh E, Smith RC et al. IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol. 2003; 170: 838-45.
38. Muller JM, Rupec RA, Baeuerle PA. Study of gene regulation by NF-κB and AP-1 in response to reactive oxygen intermediates. Methods 1997; 11: 301-12.